SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

03 Aug 2022 Evaluate
The June 2022 quarter revenue stood at Rs. 2211.70 millions, up 10.10% as compared to Rs. 2008.87 millions during the corresponding quarter last year.The Company has registered profit of Rs. 98.41  millions for the quarter ended June 2022, a growth of 13.80%  over Rs. 86.48 millions millions achieved in the corresponding quarter of last year.OP of the company witnessed a marginal growth to 289.90 millions from 276.58 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 2211.70 2008.87 10.10 2211.70 2008.87 10.10 9510.77 9369.13 1.51
Other Income 5.12 20.56 -75.10 5.12 20.56 -75.10 20.77 160.95 -87.10
PBIDT 289.90 276.58 4.82 289.90 276.58 4.82 1442.70 1625.38 -11.24
Interest 28.58 38.43 -25.63 28.58 38.43 -25.63 134.94 178.98 -24.61
PBDT 261.32 238.15 9.73 261.32 238.15 9.73 1307.76 1446.40 -9.59
Depreciation 127.98 118.28 8.20 127.98 118.28 8.20 490.36 396.78 23.58
PBT 133.34 119.87 11.24 133.34 119.87 11.24 817.40 1049.62 -22.12
TAX 34.93 33.39 4.61 34.93 33.39 4.61 182.06 246.67 -26.19
Deferred Tax -6.07 0.13 -4769.23 -6.07 0.13 -4769.23 -22.16 121.84 -118.19
PAT 98.41 86.48 13.80 98.41 86.48 13.80 635.34 802.95 -20.87
Equity 129.00 129.00 0.00 129.00 129.00 0.00 129.00 129.00 0.00
PBIDTM(%) 13.11 13.77 -4.80 13.11 13.77 -4.80 15.17 17.35 -12.56

Neuland Laboratories Share Price

15301.65 316.75 (2.11%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×